Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Pb(PfCS@UIS4) Malaria Vaccine
NCT03138096Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2017
- Primary completion
- Mar 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial in malaria (5 arms), sponsored by Radboud University Medical Center. Primary endpoints: Adverse Events in Study Groups Following Exposure to Pb(PfCS@UIS4)-Infected Mosquitoes at 15 weeks, Presence of Breakthrough Parasitemia Following Exposure to Pb(PfCS@UIS4)-Infected Mosquito Bites and 1 more. Started May 2017; status: completed.
02
Conditions
malaria
Beyond the preview
Go deeper on NCT03138096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138096.